These data suggested that the anti-inflammatory and analgesic effects of EA treatment on RA are closely related to the inhibition of innate immunity-mediated inflammatory response in the macrophages and synovial fibroblasts driven by TLR2/4-MyD88-NF-κB signaling pathway in the synovium. The gene discussed is TLR2; the disease is rheumatoid arthritis.